Efficacy and tolerability of celecoxib versus naproxen in patients with osteoarthritis of the knee: A randomized, double-blind, Double-dummy Trial

Journal of International Medical Research

Volumn 40, Issue 4, 2012, Pages 1357-1370

  Essex, M N ^a   Bhadra, P ^a   Sands, G H ^a  

^a PFIZER INC   (United States)

Author keywords

Celecoxib; Efficacy; Knee; Naproxen; Nonsteroidal anti inflammatory drugs; Osteoarthritis; Tolerability; Womac score

Indexed keywords

CELECOXIB; NAPROXEN;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; FLATULENCE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INFECTION; KNEE OSTEOARTHRITIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; PERIPHERAL EDEMA; RANDOMIZED CONTROLLED TRIAL; RASH; RHINOPHARYNGITIS; SKIN DISEASE; STOMACH DISCOMFORT; TREATMENT OUTCOME; UNITED STATES; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION;

EID: 84867530052     PISSN: 03000605     EISSN: 14732300     Source Type: Journal    
DOI: 10.1177/147323001204000414     Document Type: Article

References (43)

1. Shane Anderson A, Loeser RF: Why is osteoarthritis an age-related disease? Best Pract Res Clin Rheumatol 2010; 24: 15 - 26.
2. Zhang Y, Jordan JM: Epidemiology of osteoarthritis. Clin Geriatr Med 2010; 26: 355 369.
3. De Ceuninck F, Sabatini M, Pastoureau P: Recent progress toward biomarker identification in osteoarthritis. Drug Discov Today 2011; 16: 443 - 449.
4. Loeser RF: Age-related changes in the musculoskeletal system and the development of osteoarthritis. Clin Geriatr Med 2010; 26: 371 -386.
5. Waller C, Hayes D, Block JE, et al: Unload it: the key to the treatment of knee osteoarthritis. Knee Surg Sports Traumatol Arthrose 2011; 19: 1823 1829.
6. Salvo F, Fourrier-Réglat A, Bazin F, et al: Cardiovascular and gastrointestinal safety of NSAIDs: a systematic review of meta-analyses of randomized clinical trials. Clin Pharmacol Ther 2011; 89: 855 -866.
7. Lee A, Cooper MG, Craig JC, et al Effects of nonsteroidal anti-inflammatory drugs on postoperative renal function in adults with normal renal function. Cochrane Database Syst Rev 2007; (2): CD002765.
8. Kearney PM, Baigent C, Godwin J, et al: Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006; 332: 1302-1308.
9. McGettigan P, Henry D: Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med 2011;8:el001098.
10. Solomon DH, Glynn RJ, Rothman KJ, et al: Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups. Arthritis Rheum 2008; 59: 1097 1104.
11. Peura DA, Goldkind L: Balancing the gastrointestinal benefits and risks of nonselective NSAIDs. Arthritis Res Ther 2005; 7(suppl4):S7-S13. (Pubitemid 41646249)
12. Garcia Rodriguez LA, Jick H: Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal antiinflammatory drugs. Lancet 1994; 343: 769 772.
13. American Academy of Orthopaedic Surgeons (AAOS): Treatment of Osteoarthritis of the Knee (Non-arthroplasty). Full Guideline. Rosemont: AAOS, 2008 (available at: http://www.aaos. org/research/guidelines/oakguideline.pdf).
14. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 2000; 43: 1905 1915.
15. Jordan KM, Arden NK, Doherty M, el al: EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003; 62:1145 - 1155.
16. National Institute for Health and Clinical Excellence (NICE): Osteoarthritis: the Care and Management of Osteoarthritis in Adults. NICE Clinical Guideline 59, London: NICE,2008 (available at: http://www.nice.org.uk/ nicemedia/live/11926/39557/39557.pdf).
17. Zhang W, Moskowitz RW, Nuki G, et al: OARSI recommendations for the management of hip and knee osteoarthritis, part H: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008; 16: 137 - 162.
18. Zhang W, Nuki G, Moskowitz RW, et al: OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage 2010; 18: 476 499.
19. Hochberg MC, Altman RD, April KT, et al: American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken) 2012; 64: 465 -474.
20. Bensen WG, Fiechtner JJ, McMillen JI, et al: Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc 1999; 74: 1095 -1105.
21. Deeks JJ, Smith LA, Bradley MD: Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ 2002; 325: 619.
22. Kivitz AJ, Moskowitz RW, Woods E, et al: Comparative efficacy and safety of celecoxib and naproxen in the treatment of osteoarthritis of the hip. J Int Med Res 2001; 29: 467 - 479.
23. McKenna F, Borenstein D, Wendt H, et al: Celecoxib versus diclofenac in the management of osteoarthritis of the knee. Scand J Rheumatol 2001; 30: 11 - 18.
24. Pincus T, Koch G, Lei H, et al: Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis. Ann Rheum Dis 2004; 63: 931 -939.
25. Singh G, Fort JG, Goldstein JL, et al: Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Am J Med 2006; 119: 255 - 266.
26. Williams GW, Hubbard RC, Yu SS, et al: Comparison of once-daily and twice-daily administration of celecoxib for the treatment of osteoarthritis of the knee. Clin Ther 2001; 23: 213-227. (Pubitemid 32231112)
27. MeIo Gomes JA, Roth SH, Zeeh J, et al: Doubleblind comparison of efficacy and gastroduodenal safety of diclofenac/misoprostol, Piroxicam, and naproxen in the treatment of osteoarthritis. Ann Rheum Dis 1993; 52: 881 885.
28. Frakes EP, Risser RC, Ball TD, et al Duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, doubleblind, placebo-controlled trial. Curr Med Res Opin 2011; 27: 2361 - 2372.
29. Altman R, Asch E, Bloch D, et al: Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 1986; 29: 1039 -1049.
30. World Medical Association (WMA): WMA Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. Ferney-Voltaire: WMA (available at: http:// www.wma.net/en/30publications/10policies/b3 /index.html).
31. International Conference on Harmonisation: Guideline for Good Clinical Practice. ICH Harmonised Tripartite Guideline. Geneva: ICH, 1997 (available at: http://www.ich.org/ products/guidelines/efficacy/article/efficacyguidelines. html).
32. US Food and Drug Administration (FDA): Clinical Trials Guidance Documents. Silver Spring: FDA (available at: http://www.fda.gov/ RegulatoryInformation/Guidances/ucml22046 .htm).
33. Western Ontario and McMaster Universities (WOMAC) : WOMAC 3.1 Index: Knee and Hip Osteoarthritis Index (available at: http://www.womac.org/womac/index. htm).
34. Dimenäs E, Glise H, Hallerbäck B, et al Wellbeing and gastrointestinal symptoms among patients referred to endoscopy owing to suspected duodenal ulcer. Scand J Gastroenterol 1995; 30: 1046 - 1052.
35. McCorkle R, Young K: Development of a symptom distress scale. Cancer Nurs 1978; 1: 373-378.
36. MedDRA-MSSO: Medical Dictionary for Regulatory Activities (MedDRA) Maintenance and Support Services Organization (MSSO) (available at: http://www.meddramsso.com/).
37. Niculescu L, Li C, Huang J, et al: Pooled analysis of GI tolerability of 21 randomized controlled trials of celecoxib and nonselective NSAIDs. Curr Med Res Opin 2009; 25: 729 - 740.
38. Mallen SR, Essex MN, Zhang R: Gastrointestinal tolerability of NSAIDs in elderly patients: a pooled analysis of 21 randomized clinical trials with celecoxib and nonselective NSAIDs. Curr Med Res Opin 2011; 27: 1359 - 1366.
39. Silverstein FE, Faich G, Goldstein JL, et al: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAJWA 2000; 284: 1247 - 1255.
40. US Food and Drug Administration (FDA): COX2 Selective (Includes Bextra, Celebrex, and Vioxx) and Non-selective Non-steroidal Anti-inflammatory Drugs (NSAlDs). Silver Spring: FDA (available at: http://www.fda.gov/Drugs/DrugSafety/ Post marketDrugSafetylnformationforPatientsand Providers/ucml03420.htm).
41. Adebajo A: Non-steroidal anti-inflammatory drugs for the treatment of pain and immobilityassociated osteoarthritis: consensus guidance for primary care. BMC Fam Pract 2012; 13: 23.
42. Fleischmann R, Tannenbaum H, Patel NP, et al: Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: a randomised controlled trial in patients with osteoarthritis. BMC Musculoskelet Disord 2008; 9: 32.
43. Sawitzke AD, Shi H, Finco MF, et al: Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT. Ann Rheum Dis 2010; 69: 1459 - 1464.